Breast Cancer Clinical Trial
A Study of YM155 Plus Docetaxel as First-Line Treatment in Subjects With HER2 Negative Metastatic Breast Cancer
Summary
The purpose of this study is to evaluate survival, response rate, safety and tolerability of YM155 given in combination with docetaxel as first-line treatment in subjects with human epidermal growth factor 2 non-overexpressing (HER2 negative) metastatic breast cancer.
Full Description
This is an outpatient study. All subjects enrolled in this study will receive a combined regimen of YM155 and docetaxel or docetaxel alone given during 21 day cycles. Each subject will be assessed at the end of each cycle to determine if the subject can continue to the next cycle. Each subject assigned to receive YM155 in combination with docetaxel will be eligible to continue receiving the combination regimen in this study until one of the discontinuation criteria is met.
If a subject discontinues treatment with at least stable disease (SD) that subject will complete follow-up visits every 12 weeks for 2 years or until initiating another systemic anti-breast cancer treatment, exhibiting progressive disease (PD), or death.
Each subject will be contacted by the study site every 12 weeks for survival following the End of Treatment Visit. The contacts will continue until death or for no more than 2 years.
Eligibility Criteria
Inclusion Criteria:
Histologically- or cytologically-proven adenocarcinoma of the breast that is HER2 negative. Subjects with hormone receptor positive or negative status are eligible. Additionally, subjects with triple negative status (meaning estrogen receptor negative, progesterone receptor negative and HER2 negative) are eligible
No prior chemotherapy regimen for metastatic breast cancer
Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1 at the Baseline Visit
The subject's life expectancy is estimated to be > 12 weeks at the Baseline Visit
The subject must be non-pregnant and non-lactating. All sexually active subjects of childbearing potential must agree to use an adequate method of contraception throughout the study period
Exclusion Criteria:
Hypersensitivity to docetaxel or polysorbate 80
Neuropathy ≥ Grade 2 at the Baseline Visit
Known brain or leptomeningeal metastasis as assessed through medical history review and physical examination
The subject has known Human Immunodeficiency Virus (HIV), Hepatitis B surface Antigen or hepatitis C antibody
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 30 Locations for this study
Los Angeles California, 90057, United States
Pleasant Hill California, 94523, United States
Lakeland Florida, 33805, United States
Detroit Michigan, 48201, United States
Missoula Montana, 59802, United States
Hickory North Carolina, 28602, United States
Canton Ohio, 44718, United States
Brussels , 1000, Belgium
Charleroi , 6000, Belgium
Wilrijk , 2610, Belgium
Prague 10 , 100 3, Czech Republic
Prague , 180 8, Czech Republic
Augsburg , 86150, Germany
Erlangen , 91054, Germany
Kiel , 24105, Germany
Trier , 54290, Germany
Dublin , 4, Ireland
Dublin , 8, Ireland
Dublin , 9, Ireland
Warsaw , 02-78, Poland
Wroclaw , 51-12, Poland
Chelyabinsk , 45407, Russian Federation
Kursk , 30503, Russian Federation
Moscow , 11547, Russian Federation
Pyatigorsk , 35750, Russian Federation
Saint Petersburg , 18964, Russian Federation
Saint Petersburg , 19702, Russian Federation
Samara , 44303, Russian Federation
Tula , 30005, Russian Federation
Nottingham , NG5 1, United Kingdom
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.